AdaptHealth Corp. (AHCO)
NASDAQHealth CareMedical - DevicesSnapshot 2026-10-29
$5.93-1.66%
Close 2026-10-29 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-10-29
Research Workspace
Put AHCO beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (4q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Annual revenue reaches about $3.51 billion: Revenue guidance: $2.85B to $2.89B.
View ThesisRevenue is growing steadily — about 4% over the past year.
View GrowthMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is highly volatile — it swings about 2% on a typical day and fell roughly 61% in its worst 12-month stretch.
View RiskAHCO’s thesis rests on focusing Sleep and Respiratory Health while revenue growth improves. Revenue growth rose from 5.4% to 12.7%, though Q2 FY2026 earnings missed. AHCO trades at 12× P/E versus a 30× peer median. The price reflects less growth than our forecast, which makes this peer gap relevant. Our model puts the next-quarter miss probability near 49%. The primary pillar is broken: annual revenue guidance of $2.85 billion to $2.89 billion falls short of the stated $3.51 billion. Peer multiples imply a price about 50% above where it trades; the read is provisional.
Trailing returns as of 2026-10-29. AHCO is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 7 analysts currently covering AHCO (as of Oct 2026).
Based on 6 Wall Street analysts offering 12-month price targets for AHCO in the last 4 months.
Continue this research
Compare AHCO with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| AHCO Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 6 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put AHCO next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Focus portfolio on core Sleep and Respiratory Health businesses
Focus on scale aligns with core Sleep and Respiratory Health.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $5.93
The last 12 months of price, then the range of analyst 12-month targets from today’s $5.93.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
